Louis Catalano, MD
Neurology · Greensburg, PANPI 1720046394
Payments from drug & device makers
Across 235 payments — averaging $131.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$21K
- AbbVie$6K
- AstraZeneca$574
- Eisai Inc.$391
- Genentech USA, Inc.$375
- EMD Serono, Inc.$199
- plus $2K from 28 others
What the payments were for
- Consulting fees$3,67512%
- Speaking & faculty fees$17,75157%
- Travel & lodging$2,9109%
- Food & beverage$6,57721%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 68 | $21,417 |
| AbbVie(2 entities) | 70 | $5,722 |
| AstraZeneca | 7 | $574 |
| Eisai Inc. | 17 | $391 |
| Genentech USA, Inc. | 5 | $375 |
| EMD Serono, Inc. | 2 | $199 |
| Acadia Pharmaceuticals Inc | 7 | $170 |
| Livanova USA, Inc. | 3 | $166 |
| Greenwich Biosciences, Inc. | 4 | $159 |
| Pfizer | 9 | $152 |
| Mallinckrodt Enterprises LLC | 2 | $145 |
| Argenx US, Inc. | 3 | $142 |
| Skeletal Dynamics Inc | 1 | $133 |
| Biohaven Pharmaceuticals, Inc. | 2 | $132 |
| Biogen | 3 | $127 |
| UCB, Inc. | 2 | $119 |
| Jazz Pharmaceuticals Inc. | 1 | $116 |
| Acorda Therapeutics, Inc | 1 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| MDD US Operations, LLC | 3 | $87 |
| Novartis | 3 | $67 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Amneal Pharmaceuticals LLC | 3 | $52 |
| Lilly USA, LLC | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Boston Scientific | 1 | $26 |
| Abbott | 1 | $26 |
| Revance Therapeutics, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
| Bio Products Laboratory USA, Inc. | 1 | $16 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,964 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 31 | $558,456 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 113 | $441,126 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $431,329 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 23 | $331,286 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $151,371 |
| TysabriNatalizumab | 13 | $108,374 |
| Aimovig AutoinjectorErenumab-Aooe | 26 | $22,598 |
| QuliptaAtogepant | 11 | $15,586 |
| Dalfampridine ErDalfampridine | 11 | $11,138 |
| Emgality PenGalcanezumab-Gnlm | 14 | $8,968 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 101 | $8,574 |
| Rasagiline Mesylate | 25 | $6,839 |
| DilantinPhenytoin Sodium Extended | 25 | $6,516 |
| Carbamazepine ErCarbamazepine | 59 | $6,411 |
| Gabapentin | 200 | $4,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Octagam, Dilantin | $152 | $716,34369 claims |
| BiogenTysabri | $127 | $108,37413 claims |
| AbbVieQulipta | $5,722 | $15,58611 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $52 | $1,16524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Greensburg
- Michael MazowieckiGreensburg$536K
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.